Format
Sort by
Items per page

Send to

Choose Destination

Links from pubmed

Items: 1 to 20 of 94

1.
2.

Expression, purification and biological characterization of human vasostatin120-180 in Pichia pastoris.

Lin Y, Yang X, Lu M, Zhuang H, Hua ZC.

Protein Expr Purif. 2013 Dec;92(2):141-7. doi: 10.1016/j.pep.2013.09.016. Epub 2013 Oct 1.

PMID:
24096091
3.

A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.

Sun Q, Xu Q, Dong X, Cao L, Huang X, Hu Q, Hua ZC.

Int J Cancer. 2008 Aug 15;123(4):942-50. doi: 10.1002/ijc.23537.

4.

Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.

Lin Y, Peng N, Li J, Zhuang H, Hua ZC.

Mol Cancer. 2013 Jun 8;12:54. doi: 10.1186/1476-4598-12-54.

5.

Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.

Zhao G, Yuan C, Bian C, Hou X, Shi X, Ye X, Huang Z, Huang M.

Protein Expr Purif. 2006 Sep;49(1):71-7. Epub 2006 May 20.

PMID:
16806969
6.

Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.

Kim KS, Hong YK, Lee Y, Shin JY, Chang SI, Chung SI, Joe Y.

Exp Mol Med. 2003 Dec 31;35(6):578-85.

7.

Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.

Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, Olivero WC, Rao JS.

Oncogene. 2002 Nov 7;21(51):7824-30.

8.

Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor.

Hu XW, Duan HF, Gao LH, Pan SY, Li YM, Xi Y, Zhao SR, Yin L, Li JF, Chen HP, Wu CT.

Cancer Biol Ther. 2008 May;7(5):651-9. Epub 2008 May 28.

PMID:
18245952
9.

Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.

Cancer Res. 2005 Sep 1;65(17):7775-81.

10.

A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.

Rettenberger P, Wilhelm O, Oi H, Weidle UH, Goretzki L, Koppitz M, Lottspeich F, König B, Pessara U, Kramer MD, et al.

Biol Chem Hoppe Seyler. 1995 Oct;376(10):587-94.

PMID:
8590627
11.

[Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].

Zhu F, Xing G, He F.

Zhonghua Zhong Liu Za Zhi. 2001 Mar;23(2):115-7. Chinese.

PMID:
11783013
12.

Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.

Su M, Chang W, Zhang K, Cui M, Wu S, Xu T.

Oncol Rep. 2016 Feb;35(2):1179-85. doi: 10.3892/or.2015.4448. Epub 2015 Nov 25.

PMID:
26718643
13.

Expression, purification and characterization of recombinant human angiogenin in Pichia pastoris.

Xia WR, Fu WL, Cai L, Cai X, Wang YY, Zou MJ, Xu DG.

Biosci Biotechnol Biochem. 2012;76(7):1384-8. Epub 2012 Jul 7.

14.

A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.

Kobayashi H, Sugino D, She MY, Ohi H, Hirashima Y, Shinohara H, Fujie M, Shibata K, Terao T.

Eur J Biochem. 1998 May 1;253(3):817-26.

15.

Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.

Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M, Rao JS.

PLoS One. 2010 Aug 27;5(8):e12458. doi: 10.1371/journal.pone.0012458.

16.
17.

Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.

Lee SB, Oh HK, Kim HK, Joe YA.

Protein Expr Purif. 2006 Nov;50(1):1-8. Epub 2006 Jun 9.

PMID:
16854593
18.

A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.

Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA.

FASEB J. 2000 Jul;14(10):1400-10.

PMID:
10877833
19.

Purification and characterization of recombinant murine endostatin in E. coli.

You WK, So SH, Lee H, Park SY, Yoon MR, Chang SI, Kim HK, Joe YA, Hong YK, Chung SI.

Exp Mol Med. 1999 Dec 31;31(4):197-202.

20.

Supplemental Content

Support Center